Table 2.
Clinical characteristics of the subjects in the verification phase.
| Clinical characteristics | AITD (n = 10) | TED, mild (n = 10) | TED, severe (n = 10) | Controls (n = 10) |
|---|---|---|---|---|
| Male, n (%) | 2 (20) | 2 (20) | 6 (60) | 3 (30) |
| Age, yrs, median (range) | 59.5 (43–67) | 53.0 (40–63) | 58.5 (43–86) | 61.5 (53–72) |
| Smokers, n (%) | 0 | 1 (10) | 2 (20) | |
| Duration of AITD, mth, median (range) | 48 (7–480) | 31.5 (6–252) | 5.5 (1–168) | |
| Graves’ disease | 7 (70) | 9 (90) | 10 (100) | |
| CAS (/10), median, range | NA | 0 (0–3) | 5 (4–7) | |
| TRAb, IU/L (reference < 1.5), median (range) | 1.9 (0.7–40) | 3.4 (0–16.3) | 3.8 (0.8–13.8) | |
| FT4, pmol/L (reference 8.8–14.4), median (range) | 12.2 (10.3–16.7) | 13.4 (5.4–25.2) | 14.0 (9.7–29.5) | |
| TSH,mIU/L (reference 0.65–3.70), median (range) | 1.68 (0.067–3.07) | 0.98 (0.004–3.59) | 0.223 (0.006–3.69) |